U.S. Markets closed

Sarepta Therapeutics (SRPT) Worth Considering: Stock Surges 18.0%

Zacks Equity Research

Sarepta Therapeutics, Inc. (SRPT) was a big mover last session, as its shares advanced about 18% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. The uptrend is continuing for this biotechnology company, with the stock surging more than 34% in the past one-month time period.

The company has seen 6 positive revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting that more solid trading could be ahead for SRPT. So make sure to keep an eye on this stock going forward to see if this recent jump turns into more strength down the road.

Sarepta Therapeutics currently has a Zacks Rank #3 (Hold) and its Earnings ESP is positive.

Some better performing biotechnology stocks include Affymetrix Inc. (AFFX), Biogen Idec Inc. (BIIB) and Gilead Sciences Inc. (GILD). All these carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Read the Full Research Report on GILDRead the Full Research Report on AFFXRead the Full Research Report on BIIBRead the Full Research Report on SRPTZacks Investment Research